<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02179151</url>
  </required_header>
  <id_info>
    <org_study_id>ZAF-311</org_study_id>
    <nct_id>NCT02179151</nct_id>
  </id_info>
  <brief_title>Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome</brief_title>
  <acronym>bestPWS</acronym>
  <official_title>Randomized, Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Subcutaneous Beloranib in Suspension) in Obese Subjects With Prader-Willi Syndrome to Evaluate Total Body Weight, Food-related Behavior, and Safety Over 6 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zafgen, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zafgen, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate efficacy and safety of ZGN-440 (beloranib) in obese
      adolescent and adult subjects with Prader-Willi Syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 3, Randomized, Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Subcutaneous
      Beloranib in Suspension) in Obese Subjects with Prader-Willi Syndrome to Evaluate Total Body
      Weight, Food-related Behavior, and Safety Over 6 Months
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    FDA Clinical Hold
  </why_stopped>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in total body weight</measure>
    <time_frame>Baseline to Week 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in hyperphagia-related behavior as measured by total score of a Hyperphagia Questionnaire</measure>
    <time_frame>Baseline to Week 29</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in LDL cholesterol</measure>
    <time_frame>Baseline to Week 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HDL cholesterol</measure>
    <time_frame>Baseline to Week 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total body mass as measured by DXA</measure>
    <time_frame>Baseline to Week 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total body fat mass as measured by DXA</measure>
    <time_frame>Baseline to Week 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in triglyceride</measure>
    <time_frame>Baseline to Week 29</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Prader-Willi Syndrome</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intervention: ZGN-440 Placebo for Injectable Suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZGN-440 Injectable Suspension (1.8 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: ZGN-440 for Injectable Suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZGN-440 Injectable Suspension (2.4 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: ZGN-440 for Injectable Suspension</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZGN-440 for Injectable Suspension</intervention_name>
    <description>Subjects will receive ZGN-440 twice weekly subcutaneous injections for up to 28 weeks.</description>
    <arm_group_label>ZGN-440 Injectable Suspension (1.8 mg)</arm_group_label>
    <arm_group_label>ZGN-440 Injectable Suspension (2.4 mg)</arm_group_label>
    <other_name>ZGN-440</other_name>
    <other_name>Beloranib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZGN-440 Placebo for Injectable Suspension</intervention_name>
    <description>Subjects will receive placebo twice weekly subcutaneous injections for up to 28 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed genetic diagnosis of Prader-Willi Syndrome

          -  Age 12-65

          -  Obesity

          -  Age 12-17: BMI ≥ 95th percentile for age and gender

          -  Age 18-65: BMI ≥27 to ≤60 kg/m2

        Exclusion Criteria:

          -  Subjects living in a group home ≥ 50% of the time

          -  Recent use (within 3 months) of weight loss agents including herbal medication

          -  Poorly controlled severe psychiatric disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dennis Kim, MD</last_name>
    <role>Study Director</role>
    <affiliation>Zafgen, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD: Rady Children's Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas University Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Child Health</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Clinics of Minnesota</name>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winthrop University</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Research Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2014</study_first_submitted>
  <study_first_submitted_qc>June 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2014</study_first_posted>
  <disposition_first_submitted>January 24, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>January 24, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 26, 2017</disposition_first_posted>
  <last_update_submitted>January 24, 2017</last_update_submitted>
  <last_update_submitted_qc>January 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prader-Willi Syndrome</keyword>
  <keyword>Obesity</keyword>
  <keyword>Hyperphagia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Prader-Willi Syndrome</mesh_term>
    <mesh_term>Hyperphagia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

